title: Haptoglobin 2-2 phenotype is associated with decreased serum iron levels in endstage renal disease patients resistant to rhEPO therapy.
authors: F
authors: F
authors: Martins
authors: C
authors: C
authors: Catarino
authors: P
authors: P
authors: Rocha-Pereira
authors: F
authors: F
authors: Reis
authors: M
authors: M
authors: Sameiro-Faria
authors: V
authors: V
authors: Miranda
authors: L
authors: L
authors: Belo
authors: E
authors: E
authors: Bronze-da-Rocha
authors: E
authors: E
authors: Costa
authors: A
authors: A
authors: Santos-Silva
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006242:Haptoglobins / Q000235:genetics*; D006801:Humans; D007501:Iron / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011994:Recombinant Proteins / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: C554270:EPO protein, human; C485359:HP protein, human; D006242:Haptoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron